"A randomized, single-blind, placebo-controlled, single-center, single-dose-escalation, and multi-dose-escalation phase I trial evaluating the safety, tolerability, pharmacokinetic, and preliminary pharmacodynamic characteristics of subcutaneous RBD7022 in subjects with normal or elevated LDL cholesterol" is ongoing.
“A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects” is in IRB review in Australia aiming for Phase 1 starting Q4 2022.
"A randomized, double-blind, placebo-controlled, single-dose escalation phase Ia clinical Study to evaluate the safety and pharmacokinetics of RBD1016 in healthy subjects" has been completed in Australia.
"A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection", currently ongoing in Hong Kong, China.
“A multi-center, randomized, double-blind, placebo-controlled，2:1 parallel-group phase II clinical study to evaluate efficacy and safety of ISIS 449884 injection monotherapy in patients with type 2 diabetes mellitus with poorly controlled blood glucose following diet and exercise interventions” has been completed.
"A multi-center, randomized, double blind, placebo-controlled, 2:1 parallel-group phase II clinical study to evaluate efficacy and safety of ISIS 449884 Injection combined with metformin in patients with type 2 diabetes mellitus with poorly controlled blood glucose following Metformin monotherapy" has been completed.